Very interesting real world evidence data suggesting that vortioxetine is superior to SSRIs sertraline and citalopram in treating the cognitive impairment and associated features of long Covid syndrome psychiatrist.com/jcp/vortioxeti…

Cariprazine meaningfully effective in the treatment of anhedonia in major depressive disorder kwnsfk27.r.eu-west-1.awstrack.me/L0/https:%2F%2…

A pilot study with four patients with bipolar II disorder receiving psilocybin safely as part of the study conducted at Brain and Cognition Discovery Foundation BCDF Thanks Shakila our team put this report together pubmed.ncbi.nlm.nih.gov/40337756/

Anhedonia might mediate the increase in suicidality seen an obstructive sleep apnea pubmed.ncbi.nlm.nih.gov/40337952/

Interesting analog of LSD that is not hallucinogenic that may have therapeutic application pnas.org/doi/10.1073/pn…

A comprehensive state of the art review of bipolar II disorder a very often neglected subtype of bipolar disorder pubmed.ncbi.nlm.nih.gov/40371769/

chemogenetic activation of GLP-1-producing neurons in the nucleus tractus solitarius that project to the ventral tegmental area (VTA) decreased cocaine seeking by stimulating GABA neurons in VTA pubmed.ncbi.nlm.nih.gov/40009667/

FDA clears first blood test for diagnosis of Alzheimer’s disease fda.gov/news-events/pr…

GLP1 receptor agonists eg Ozempic are now being evaluated for the treatment of major depressive and bipolar disorder, substance use, and schizophrenia…. Part of a pivot in treatment development in psychiatry focusing on targeting metabolic therapies psychiatrictimes.com/view/insulin-i…

In persons living with depressive disorders Consideration should be given to non SSRIs as first line antidepressants if a history of trauma is reported…. need to consider more in our development of new therapeutics and how we personalise treatment pubmed.ncbi.nlm.nih.gov/40415673/

Glucagon Like Peptide-1 (GLP-1, Ozempic) are showing tremendous promise in the treatment and prevention of mental disorders. Herein, I cover the background and rationale for why we are repurposing them for these indications. youtube.com/watch?v=-9s1Fk…

Lithium continues to demonstrate replicated, evidence of reduction in suicidality thanks to James Wang from our team for leading this synthesis and bringing this together sciencedirect.com/science/authSh…

A history of trauma in person with bipolar disorder result in a different illness and treatment response compared to people without a history of trauma …. has conceptual and treatment implications thanks to Kelei and the team for putting this together pubmed.ncbi.nlm.nih.gov/40449746/

Polycystic ovarian syndrome PCOS is associated with suicidality and possibly independent of depression conceptually speaking to the insulin regulation of cognition and reward function also clinical implications thanks to Sabrina Wong from our team link.springer.com/article/10.118…

strategic imperative in psychiatry to identify therapeutics to treat disturbance in reward function ….. it’s also a strategic imperative to identify which measure to use!!! SHAPS is likely the least inadequate.. the EEfRT task likely not adequate at all authors.elsevier.com/a/1lCAqbXYiyrQ7

Simvastatin was not effective as an adjunctive treatment in major depressive disorder and obesity 2/3 had elevated inflammatory marker CRP pubmed.ncbi.nlm.nih.gov/40465256/

I was pleased to see the attention given to the link between cardiovascular disease and mental disorders at the 2025 annual meet of the European Society of Cardiology held in Madrid, Spain, in conjunction with the Inter-American Society of Cardiology… medscape.com/viewarticle/he…

A compelling molecular rationale to evaluate whether GLP1RAs (e.g.Ozempic) may modify disease trajectory in Parkinson’s disease. Result have been mixed Congrats to Serene from my research team for leading this synthesis. doi.org/10.1017/S10928…

The consequences of psychiatric drugs on eye health and pre-existing disease is underemphasized : cataracts can sometimes occur in association with some antipsychotics albeit uncommon Thanks to my team bringing this report together pubmed.ncbi.nlm.nih.gov/40505686/

Xanomeline-trospium (Cobenfy) is being evaluated in the treatment of acute mania and mixed episodes in bipolar disorder…the cholinergic-adrenergic hypothesis of bipolar disorder by Janowski in 1972 has been re-invoked. pubmed.ncbi.nlm.nih.gov/?term=McIntyre…